Divi's Laboratories vs Zydus Lifesciences: share price, P/E, ROE and financials compared
Divi's Laboratories
Zydus Lifesciences
Divi's Laboratories and Zydus Lifesciences at a glance
Divi's Laboratories and Zydus Lifesciences are both listed in Healthcare. Divi's Laboratories is the larger by market cap, at ₹2.7L Cr against ₹1.2L Cr for Zydus Lifesciences (2.3 times as large). On valuation, Zydus Lifesciences has the lower P/E (28.6× against 93.6×) and the lower price-to-book (4.29× against 16.35×). On returns and margins, Divi's Laboratories has the higher ROE (16.2% against 14.7%) and the higher operating margin (34.9% against 26.2%). Over three years, Zydus Lifesciences has faster 3-year sales growth (+16.5% against +11.0% a year) and faster 3-year profit growth (+37.0% against +12.1% a year). Divi's Laboratories carries less debt for its equity, with a debt-to-equity of 0.00× against 0.46×.
Key metrics, side by side
| Metric | Divi's LaboratoriesDIVISLAB | Zydus LifesciencesZYDUSLIFE |
|---|---|---|
| Price (₹) | 10,320.50 | 1,197.90 |
| Market cap (₹ Cr) | 2,73,977 | 1,19,491 |
| P/E | 93.6× | 28.6× (the lower figure, shaded) |
| P/B | 16.35× | 4.29× (the lower figure, shaded) |
| Dividend yield, trailing | 0.29% (the higher figure, shaded) | 0.08% |
| ROE | 16.2% (the higher figure, shaded) | 14.7% |
| ROCE | 19.0% | 19.0% |
| Operating margin (OPM) | 34.9% (the higher figure, shaded) | 26.2% |
| Net margin (NPM) | 26.0% (the higher figure, shaded) | 13.8% |
| Sales CAGR 3Y | +11.0% | +16.5% (the higher figure, shaded) |
| Profit CAGR 3Y | +12.1% | +37.0% (the higher figure, shaded) |
| Debt to equity | 0.00× (the lower figure, shaded) | 0.46× |
| Interest cover | 148.3× (the higher figure, shaded) | 19.1× |
| Net profit TTM (₹ Cr) | – | – |
| 1Y return | +49.0% (the higher figure, shaded) | +22.8% |
| Promoter holding | 51.88% | 75.01% |
Divi's Laboratories vs Zydus Lifesciences: common questions
Which is bigger, Divi's Laboratories or Zydus Lifesciences?
By market cap, Divi's Laboratories is bigger at ₹2.7L Cr, against ₹1.2L Cr for Zydus Lifesciences (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Divi's Laboratories or Zydus Lifesciences?
Divi's Laboratories trades at a P/E of 93.6× and Zydus Lifesciences at 28.6×. Zydus Lifesciences has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Divi's Laboratories or Zydus Lifesciences?
Divi's Laboratories reports a return on equity of 16.2% and Zydus Lifesciences 14.7%. Divi's Laboratories has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Divi's Laboratories or Zydus Lifesciences?
Over the last three years: Sales grew +11.0% a year at Divi's Laboratories and +16.5% at Zydus Lifesciences, so Zydus Lifesciences grew sales faster; profit grew +12.1% a year at Divi's Laboratories and +37.0% at Zydus Lifesciences, so Zydus Lifesciences grew profit faster. Past growth doesn’t predict future growth.